CO51 | Novel biomarkers of neurological damage in acute immune-mediated thrombotic thrombocytopenic purpura
Background: Central nervous system (CNS) involvement is well-documented in acute immune-mediated thrombotic thrombocytopenic purpura (iTTP). Glial fibrillary acidic protein (GFAP), a marker of astrocytic injury, and neurofilament light chain (NfL), an indicator of axonal degeneration, are emerging...
Saved in:
| Format: | Article |
|---|---|
| Language: | English |
| Published: |
PAGEPress Publications
2025-07-01
|
| Series: | Bleeding, Thrombosis and Vascular Biology |
| Subjects: | |
| Online Access: | https://www.btvb.org/btvb/article/view/261 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839627296619626496 |
|---|---|
| collection | DOAJ |
| description |
Background: Central nervous system (CNS) involvement is well-documented in acute immune-mediated thrombotic thrombocytopenic purpura (iTTP). Glial fibrillary acidic protein (GFAP), a marker of astrocytic injury, and neurofilament light chain (NfL), an indicator of axonal degeneration, are emerging biomarkers of CNS damage, as demonstrated by their associations with conditions such as stroke, dementia, and neuroinflammation. The role of these neurobiomarkers in iTTP has never been investigated.
Aims: To evaluate the association between GFAP and NfL levels and acute iTTP event. Methods: This case-control study included iTTP patients referred to our center at presentation of their first iTTP episode and age-and sex-matched healthy controls. Serum GFAP and NfL levels were quantified using Simoa technology on a SR-X analyzer (Quanterix). Patients with impaired renal function were excluded. We also assessed the association between these neurobiomarkers and the presence of neurological signs or symptoms among acute iTTP patients.
Results: Thirty-seven iTTP patients were enrolled (Table 1), including 19 with neurological signs or symptoms and 18 without, and 39 healthy controls. GFAP levels were significantly higher in iTTP patients compared with controls (median difference 52 pg/ml; 95% CI 31–76; p<0.001), whereas NfL levels showed no significant difference. The association of GFAP with iTTP was not influenced by age and sex (adjusted OR per 10 units increase: 1.47; 95% CI 1.20–1.79; p<0.001). At logistic regression, neither GFAP nor NfL were associated with the presence of neurological signs or symptoms at presentation of acute iTTP, even when adjusted for potential confounders (age, sex, BMI and creatinine).
Conclusions: GFAP was associated with acute iTTP at presentation, possibly reflecting greater astrocytic involvement or injury. Its increase in patients without overt neurological signs or symptoms may suggest the presence of subclinical damage in both groups of individuals, highlighting the need for long-term observation of iTTP patients.
|
| format | Article |
| id | doaj-art-6069cbab9d2b47a091a19c902be53f5f |
| institution | Matheson Library |
| issn | 2785-5309 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Bleeding, Thrombosis and Vascular Biology |
| spelling | doaj-art-6069cbab9d2b47a091a19c902be53f5f2025-07-16T13:36:22ZengPAGEPress PublicationsBleeding, Thrombosis and Vascular Biology2785-53092025-07-014s110.4081/btvb.2025.261CO51 | Novel biomarkers of neurological damage in acute immune-mediated thrombotic thrombocytopenic purpura Background: Central nervous system (CNS) involvement is well-documented in acute immune-mediated thrombotic thrombocytopenic purpura (iTTP). Glial fibrillary acidic protein (GFAP), a marker of astrocytic injury, and neurofilament light chain (NfL), an indicator of axonal degeneration, are emerging biomarkers of CNS damage, as demonstrated by their associations with conditions such as stroke, dementia, and neuroinflammation. The role of these neurobiomarkers in iTTP has never been investigated. Aims: To evaluate the association between GFAP and NfL levels and acute iTTP event. Methods: This case-control study included iTTP patients referred to our center at presentation of their first iTTP episode and age-and sex-matched healthy controls. Serum GFAP and NfL levels were quantified using Simoa technology on a SR-X analyzer (Quanterix). Patients with impaired renal function were excluded. We also assessed the association between these neurobiomarkers and the presence of neurological signs or symptoms among acute iTTP patients. Results: Thirty-seven iTTP patients were enrolled (Table 1), including 19 with neurological signs or symptoms and 18 without, and 39 healthy controls. GFAP levels were significantly higher in iTTP patients compared with controls (median difference 52 pg/ml; 95% CI 31–76; p<0.001), whereas NfL levels showed no significant difference. The association of GFAP with iTTP was not influenced by age and sex (adjusted OR per 10 units increase: 1.47; 95% CI 1.20–1.79; p<0.001). At logistic regression, neither GFAP nor NfL were associated with the presence of neurological signs or symptoms at presentation of acute iTTP, even when adjusted for potential confounders (age, sex, BMI and creatinine). Conclusions: GFAP was associated with acute iTTP at presentation, possibly reflecting greater astrocytic involvement or injury. Its increase in patients without overt neurological signs or symptoms may suggest the presence of subclinical damage in both groups of individuals, highlighting the need for long-term observation of iTTP patients. https://www.btvb.org/btvb/article/view/261Platelet alterations and genetic conditions. |
| spellingShingle | CO51 | Novel biomarkers of neurological damage in acute immune-mediated thrombotic thrombocytopenic purpura Bleeding, Thrombosis and Vascular Biology Platelet alterations and genetic conditions. |
| title | CO51 | Novel biomarkers of neurological damage in acute immune-mediated thrombotic thrombocytopenic purpura |
| title_full | CO51 | Novel biomarkers of neurological damage in acute immune-mediated thrombotic thrombocytopenic purpura |
| title_fullStr | CO51 | Novel biomarkers of neurological damage in acute immune-mediated thrombotic thrombocytopenic purpura |
| title_full_unstemmed | CO51 | Novel biomarkers of neurological damage in acute immune-mediated thrombotic thrombocytopenic purpura |
| title_short | CO51 | Novel biomarkers of neurological damage in acute immune-mediated thrombotic thrombocytopenic purpura |
| title_sort | co51 novel biomarkers of neurological damage in acute immune mediated thrombotic thrombocytopenic purpura |
| topic | Platelet alterations and genetic conditions. |
| url | https://www.btvb.org/btvb/article/view/261 |